Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Part of paid clinical trials in New York, New York.

Sponsor
Celgene
Study ID
NCT02935790
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage III/Stage IV melanoma.

Key Dates

Start date
Sep 30, 2016
Status verified
Aug 2017
Primary completion
Apr 7, 2017
Completion
Apr 7, 2017

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ACY-241 combo with Ipi and Nivo
    ACY-241 in Combination with Ipilimumab and Nivolumab

Primary Outcome Measure

Number of Dose Limiting Toxicities defining the MTD [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone Medical CenterNew YorkNew York10016-

Find similar trials in New York, NY

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
NYU Langone Medical Center· New York, NY

Related Studies